CONSUN PHARMAC.GR.HD -10
Research CONSUN PHARMAC.GR.HD -10 (C1P) on Bullrun: market cap EUR 1.20B, P/E 8.9, dividend yield 5.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerC1P
- ExchangeF
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 1.20B
- P/E8.9
- Dividend yield5.4%
- Financial periodFY2025
- RevenueCNY 3.42B
- Revenue growth15.2%
- Net incomeCNY 1.08B
- Free cash flowCNY 1.14B
- Gross margin78.0%
Valuation Snapshot
latest market cap is EUR 1.20B; P/E is 8.9; dividend yield is 5.4%.
Peer valuation comparison
Latest P/E is 8.94x versus a Healthcare sector median of 24.46x (63.5% below).
Latest dividend yield is 5.41% versus a Healthcare sector median of 2.11% (156.4% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 3.42B | CNY 1.08B | CNY 1.14B | 78.0% | 1.26 | CNY 1.23B | CNY 212.92M | CNY 4.54B |
| FY2024 | CNY 2.97B | CNY 910.46M | CNY 977.99M | 75.6% | 1.09 | CNY 2.91B | CNY 267.17M | CNY 4.10B |
| FY2023 | CNY 2.59B | CNY 784.53M | CNY 766.41M | 74.2% | 0.98 | CNY 2.75B | CNY 511.53M | CNY 3.63B |
| FY2022 | CNY 2.34B | CNY 682.91M | CNY 896.09M | 75.3% | 0.86 | CNY 2.45B | CNY 460.18M | CNY 3.15B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | EUR 1.20B | 8.9 | 6.2% | 0.09 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.09 EUR, yield 5.4%.
| Year | Dividends/share |
|---|---|
| FY2025 | 0.07 CNY |
| FY2024 | 0.1 CNY |
| FY2023 | 0.05 CNY |
| FY2022 | 0.02 CNY |
| FY2021 | 0.03 CNY |
About CONSUN PHARMAC.GR.HD -10
Consun Pharmaceutical Group Limited, together with its subsidiaries, produces and sells pharmaceutical products in Mainland China. It operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granules for chronic renal failure; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is CONSUN PHARMAC.GR.HD -10's market cap?
CONSUN PHARMAC.GR.HD -10's market capitalization is EUR 1.20B.
What is CONSUN PHARMAC.GR.HD -10's P/E ratio?
CONSUN PHARMAC.GR.HD -10's price-to-earnings (P/E) ratio is 8.9.
Does CONSUN PHARMAC.GR.HD -10 pay a dividend?
CONSUN PHARMAC.GR.HD -10 has a dividend yield of 5.4%.
What does CONSUN PHARMAC.GR.HD -10 do?
Consun Pharmaceutical Group Limited, together with its subsidiaries, produces and sells pharmaceutical products in Mainland China. It operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical.